Sanofi Eyes More Acquisitions
Despite this multi-billion-dollar leap, Sanofi made clear it still has room to maneuver. The company recently announced plans to acquire Vigil Neuroscience for $470 million, a move designed to crack into the neurodegenerative disease market with a promising candidate aimed at Alzheimer’s.
With the Blueprint acquisition, Sanofi is doubling down on its belief that precision medicine in rare diseases and immunology is not just the future of biotech—it’s the present battleground for dominance.
Sanofi and Blueprint representatives did not immediately respond to requests for comment Monday. But one thing is clear: the race to innovate — and to acquire innovation — is heating up, and Sanofi is charging forward at full throttle.
